Figure 1 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors

作者：Jun Sato, Yuki Katsuya, Takafumi Koyama, Toshio Shimizu, Yasushi Tanoue, Maki Yamamoto, Hirokazu Tozaki, Eiji Takahara, Shingo Shoji, Akio Mizutani, Daisuke Morishita, Robert Oda, Hiroshi Miyake, Kan Yonemori, Noboru Yamamoto · 年份：2026 · DOI：10.1158/1078-0432.33143310 · 研究领域：Medicine、Nuclear medicine、Internal medicine、Oncology、Urology、Mathematics、Chemistry

<p>PK and PD of rogocekib. Mean plasma rogocekib concentrations following oral administration are shown (<b>A</b>). Error bars represent standard deviation (S.D.) values for each time point. Mean fold changes in THAP9-AS1 (<b>B</b>) and S6K (<b>C</b>) RNA markers following rogocekib administration are shown. Fold changes are presented as values relative to each patient’s predose baseline; accordingly, the predose value corresponds to a fold change of 1.0. Error bars represent S.D. values for each time point. For both PK and PD graphs, data from patients with a dose of 70 mg twice weekly from cohorts A and D have been combined for presentation purposes.</p>